Evidence map›Paper›PMID 40874067›Full record

ArticleJournal of mood and anxiety disorders2025

Clinical decision support for pharmacologic management of treatment-resistant depression with augmented large language models.

Roy H Perlis, Pilar F Verhaak, Joseph Goldberg, Cristina Cusin, Michael Ostacher, Gin S Malhi, Carlos A Zarate, Richard C Shelton, Dan V Iosifescu, Mauricio Tohen and 3 more

Abstract read
In one paragraph

Article in Journal of mood and anxiety disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Roy H PerlisCenter for Quantitative Health and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States.
Pilar F VerhaakCenter for Quantitative Health and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States.
Joseph GoldbergDepartment of Psychiatry, Mt. Sinai School of Medicine, New York, NY, United States.
Cristina CusinDepartment of Psychiatry, Harvard Medical School, Boston, MA, United States.
Michael OstacherDepartment of Psychiatry, Stanford University School of Medicine, Stanford, CA, United States.
Gin S MalhiAcademic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Carlos A ZarateSection on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, United States.
Richard C SheltonDepartment of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Dan V IosifescuNYU School of Medicine and Nathan Kline Institute, NY, United States.
Mauricio TohenDepartment of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, United States.
Manish Kumar JhaDepartment of Psychiatry, UT Southwestern Medical Center, Dallas, TX, United States.
Martha SajatovicUniversity Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
Michael BerkSchool of Medicine, Deakin University and Barwon Health, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We evaluated whether a large language model could assist in selecting psychopharmacological treatments for adults with treatment-resistant depression. Methods: We generated 20 clinical vignettes reflecting treatment-resistant depression among adults based on distributions drawn from electronic health records. Each vignette was evaluated by 2 expert psychopharmacologists to determine and rank the 5 best next-step pharmacologic interventions, as well as contraindicated or poor next-step treatments. Vignettes were then presented in random order, permuting gender and race, to a large language model (Qwen 2.5:7B), augmented with a synopsis of published treatment guidelines. Model output was compared to expert rankings, as well as to those of a convenience sample of community clinicians and an additional group of expert clinicians. Results: The augmented model prioritized the expert-designated optimal choice for 114/320 vignettes (35.6 %, 95 % CI 30.6 %-41.0 %; Cohen's kappa = 0.34, 95 % CI 0.28-0.39). There were no vignettes for which any of the model choices were among the poor or contraindicated treatments. Results were not meaningfully different when gender or race of the vignette was permuted to examine risk for bias. A sample of community clinicians identified the optimal treatment choice for 12/91 vignettes (13.2 %, 95 % CI: 7.7-21.6 %; Cohen's kappa = 0.10, 95 % CI 0.03-0.18), while an additional group of expert psychopharmacologists identified optimal treatment for 9/140 (6.4 %, 95 %CI: 3.4-11.8 %; Cohen's kappa = 0.03, 95 % CI 0.01-0.08). Conclusion: An augmented language model demonstrated moderate agreement with expert recommendations and avoided contraindicated treatments, suggesting potential as a tool for supporting complex psychopharmacologic decision-making in treatment-resistant depression.

Indexed as

Artificial intelligenceExpert consensusMachine learningMajor depressionPsychopharmacology

Identifiers

PMID40874067
PMCPMC12378943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.